HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Actinium Pharma (AMEX:ATNM) and maintained a $50 price target.
September 07, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $50.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $50 also indicates their confidence in the company's potential growth. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100